How CRISPR Is Rewriting Medicine Faster Than Regulators Can Follow
December 29, 2025 · Frisian News
Gene-editing technology CRISPR now treats blood disorders and cancers in clinics worldwide, but governments and health agencies struggle to keep pace with its speed and cost decisions.
A clinic in London last month approved CRISPR treatment for a patient with sickle cell disease. The therapy cost 150,000 pounds and took six months to manufacture. Two years ago, no hospital outside experimental trials could offer this at all. Today, clinics in the United States, Europe, and Asia run CRISPR programs. The technology now works. Regulators have not yet agreed on how to price it, who pays, or what happens when it fails.
The speed of CRISPR's clinical use has outpaced every regulatory system designed to control it. The European Medicines Agency approves new drugs through a process that takes years. CRISPR therapies, by contrast, move from lab to patient in months because private clinics in countries with loose oversight run the treatments first. Rich patients fly to these clinics, pay cash, and return home. Their results then pressure governments to approve the same treatment domestically. Regulators follow, not lead.
Cost creates another gap that regulators cannot fill. Gene therapies using CRISPR run between 100,000 and 500,000 dollars per patient depending on the disease. Health systems in wealthy countries struggle to fund even one case per year. Meanwhile, biotech firms point to the personalized nature of each therapy and claim high prices reflect real costs. No country has yet forced prices down, and no country has agreed on who should bear the cost when a therapy fails to work. This leaves ordinary people choosing between saving for a house and saving their life.
The real problem runs deeper than speed or cost. CRISPR works by cutting DNA and rewriting genetic code inside living cells. Off-target cuts can cause mutations and cancer years later. Long-term safety data does not exist because the technology is too new. Regulators in most countries require five to ten years of follow-up data before approving any drug. CRISPR therapies have perhaps two years of data at best. Patients sign consent forms acknowledging unknown risks, but governments have not decided whether this consent alone justifies wider use.
Small countries face a choice: ban CRISPR and watch citizens seek treatment abroad, or permit it and take responsibility for unknown harms. Large countries delay, hoping other nations run the experiments first. Meanwhile, researchers and clinics move forward. The technology will not wait for bureaucrats to catch up. By the time regulators agree on rules, CRISPR will have moved on to other diseases, other cell types, other complexities that nobody can yet predict.
In klinyk yn Londen foarje moanne keurt CRISPR-behanneling goed foar in pasint mei sikeselselanemie. De terapi kosten 150.000 pûn en naam seis moannten yn beslag om te produsearjen. Twa jier lyn koe gjin sykehûs bûten eksperimintele ûndersieken dit oanbiede. Hjoed rôlje klinieken yn de Feriene Staten, Europa en Azië CRISPR-programma's. De teknyk wurket no. Regelgevers hawwe noch net oerienkommene hoe't se te prisjen, wa betalt, of wat der bart as it mislukt.
De snelheid fan CRISPR's kliniske gebrûk hat elk regelgevingssysteem dat it kontrolearje moat ynhelle. It Europeesk Geneesmiddelenburo keurt nije medisinen goed fia in proses dat jierren duert. CRISPR-terapieën oersjoon fan lab nei pasint yn moannten om't partikuliere klinieken yn lannen mei los toisicht de behannellingen earst útfiere. Rjochte passinten fleagje nei dizze klinieken, betelje kontant en geare thús. Harren resultaten drukkje ferfolgens op regearingen om deselde behanneling yn heim goed te keuren. Regelgevers folgje, se liede net.
Kosten meitsje in oar gat dat regelgevers net opfolje kinne. Gentherapieën mei CRISPR koste tusken 100.000 en 500.000 dollar per pasint ôfhinklich fan de sykte. Sûnensjasystemen yn rjochte lannen striuwe om sels ien gefal per jier te finansearjen. Undertuske wize bioteknologjebedriuwen op it persoanlik karakter fan elk terapi en stelle hege prizen foar echte kosten. Gjin lân hat de prizen noch omleech dwongen, en gjin lân is oerienkommene wa de kosten betre moat as in terapi net wurket. Dit lit gewoane minsken kieze tusken sparre foar in hûs en har libben redde.
It echte probleem leit djipper as snelheid of kosten. CRISPR wurket troch DNA te snijen en genetyske koade yn libinde sellen herskrijwe. Off-target snijen kinne mutaasjes en kanker jierren letter feroarsaakje. Langetermijn-feiligheidsgegeven bestean net om't de teknyk te nij is. Regelgevers yn de measte lannen easkje fiif oant tsien jier foljochgegeven eardat se hokfoar medisyn goedkearje. CRISPR-terapieën hawwe op syn minst twa jier gegeven. Passinten ûnderskrikke tânemingsformulieren dy't unkende risiko's erkennje, mar regearingen hawwe net bepaald oft dizze tânemming allinne breedere gebrûk rechtfeardiget.
Lytse lannen stean foar in kar: CRISPR ferbjêde en toskouwen hoe't boargers yn it bûtenlân behanneling sykje, of it tastelle en ferantwurdlikheid nimme foar unkende skeade. Grutte lannen stelle út, hoopjend dat oare lannen earst eksperimentearje. Undertuske gean ûndersikers en klinieken fierder. De teknyk wacht net op ambtenaren. Kin de tiid dat regelgevers it iens binne oer regels, sil CRISPR nei oare sykten, oar seltypren, oare komplikaasjers ferplaats binne dy't nammers noch foarsjen kinne.
Published December 29, 2025 · Frisian News · Ljouwert, Fryslân